They were talking about Nurofen when the talked about commercialisation, not Voltaren. I wrote it down word for word as it was being said. No offence to Viper, but it's wrong.
I'm not saying that Voltaren aren't working with OBJ on an applicator, but the Nurofen applicator is far more advanced in its development and is close to commercialisation.
They said Voltaren came to OBJ after the Bodyguard trial for "possible product development". It's in the works but probably a bit further off unless Voltaren are able to commercialise quicker than Nurofen.
- Forums
- ASX - By Stock
- WFL
- Ann: Shareholder Update June Quarter 2016-OBJ.AX
Ann: Shareholder Update June Quarter 2016-OBJ.AX, page-54
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online